|
Dr Doug Wilson MB, ChB, PhD, FRACP, FRCPA Dr Doug Wilson is the former Senior Vice President for Medicine and Regulatory Affairs for Boehringer Ingelheim, USA, overseeing all clinical research programmes and interactions with FDA. During this period he was part of a lead team that saw 10 drugs complete successful NDAs and go onto the US market. He then became responsible for the same functions world-wide at the Companys head office in Ingelheim, Germany. He was deputy chair for some years of the companys International Medical Committee which oversaw all drugs in development globally and would assess up to 50 or more projects on a regular basis. He chaired the companys International Labeling Committee which oversaw all drug labeling and safety for drugs around the world and was a core membber of the companys International Steering Committee which supervised the companys major financial investments globally. Since his return to New Zealand he has consulted with a number of biotech groups in Australia, New Zealand and the USA and is also on the board of Neuren Pharmaceutical.
Mr Harry Karelis is the founder and Managing Director of Titan Bioventures Management Pty Ltd, the investment manager of one of the largest life-science focused private equity funds in Australia. Mr Karelis was instrumental in establishing and managing this company, called BioTech. He has led investments in drug discovery, regenerative medicine, medical devices and several other technology platform areas. Mr Karelis graduated from the University of Western Australia with a Bachelors and Honours Degree in Science, majoring in Biochemistry and Microbiology. He also has a Masters in Business Administration. He is an Associate of the Securities Institute of Australia, a Fellow of the Australian Institute of Company Directors and has qualified as a Chartered Financial Analyst (CFA) through the CFA Institute in the United States.
Dr Watt is the CEO and VP of Corporate Development for Phylogica. He is key inventor of Phylogica’s drug discovery technologies, has published more than 40 papers, and has filed more than 15 patent applications. Specialising in drug discovery biotechnology and experimental genetics,, he has attracted over $5 million in research funding from Australia and the United States for the technology underpinning Phylogica. As a top graduate from the University of Western Australia, Dr Watt won a Commonwealth Overseas Scholarship and completed his doctorate at the University of Oxford. After Post Doctoral appointments at Oxford and Harvard Universities, he returned to Western Australia in 1996 to work at the Telethon Institute for Child Health Research. Dr Watt now holds an appointment at the Institute as Honorary Research Fellow and adjunct Professor at the University of Western Australia. He is also a non-executive director of a another publicly listed biotechnology company.
Mr Bruce McHarrie has been in the biotechnology industry for over 15 years. Currently he is the Director of Finance and Business Development at the Telethon Institute for Child Health Research in Western Australia. He is responsible for the executive management of the Institute with a particular focus on commercialisation activities. Mr McHarrie joined the Institute in 1999 after returning to Western Australia from the UK, where he was Assistant Director in the Bioscience Unit at Rothschild Asset Management. The Bioscience Unit focused on investing in biotechnology and healthcare companies from the early start-up stage through to the publicly listed stage. In this capacity Mr McHarrie was invited to join the Board of a number of United Kingdom based biotechnology companies. Prior to joining Rothschild Asset Management Mr McHarrie was with Coopers and Lybrand in London, servicing a client base primarily in the financial services industry. He holds a Bachelor of Commerce Degree from the University of Western Australia and qualified as a Chartered Accountant with Deloittes.
Mr Anthony Barton has been a continued supporter of the company since inception, and is currently a substantial shareholder. Mr Barton is Executive Chairman of investment company Australian Heritage Group and brings to the board over 30 years experience encompassing capital markets, corporate finance, funds management and venture capital. MANAGEMENT Dr Paul Michael Watt BSc(Hons) D Phil Richard Hopkins Richard Hopkins completed his PhD in Molecular Parasitiology before taking up a postdoctoral appointment in yeast genetics at the Institute for Child Health Research in Wetsern Australia. His work focussed on development of a novel class of peptides, referred to as Phylomers, and the methods to integrate them into various high throughput screening platforms such as yeast two hybrid and phage display. More recently his work has focussed on engineerign peptide leads for drug development. Dr Hopkins has published over 20 peer reviewed papers and is a co-inventor on over 10 patent applications, several of which have been issued in the US and Europe. Dr Hopkins is a founding member of Phylogica and is currently employed Chief Operating Officer and VP Research. |
|
 |
